To define novel pathways that regulate susceptibility to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in non-small cell lung cancer (NSCLC), we have performed genome-wide expression profiling of microRNAs (miRs). We show that in TRAIL-resistant NSCLC cells, levels of different miRs are increased, and in particular, miR-221 and -222. We demonstrate that these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. Indeed, transfection with anti-miR-221 and -222 rendered CALU-1-resistant cells sensitive to TRAIL. Conversely, H460-sensitive cells treated with -221 and -222 pre-miRs become resistant to TRAIL. miR-221 and -222 target the 3 0 -UTR of Kit and p27 kip1 mRNAs, but interfere with TRAIL signaling mainly through p27 kip1 . In conclusion, we show that high expression levels of miR-221 and -222 are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising therapeutic targets or diagnostic tool for TRAIL resistance in NSCLC.
Introduction
MicroRNAs (miRs) are a small noncoding family of 19-25 nt RNAs that play an important role in the negative regulation of gene expression by base-pairing to complementary sites on the target mRNAs (Calin and Croce, 2006) . Currently X460 miRs have been identified in humans and other eukaryotic species (miR registry, www.sanger.ac.uk/Software/Rfam/mirna/index.shtml).
The expression pattern of miRs is often developmentally regulated and/or tissue specific, although some miRs are steadily expressed in the whole organism (Liu et al., 2004; Sempere et al., 2004) . In lower species, miRs are involved in a variety of basic processes, for example, cell proliferation and apoptosis (Xu et al., 2004; Cheng et al., 2005) , neuronal development (Smirnova et al., 2005) , fat metabolism (Xu et al., 2003) and stress response (Dresios et al., 2005) . In some studies, key target mRNAs have been identified but relatively little is known about the functional role of miRNAs in mammalian species. We do know, however, that miR-181 is involved in the control of lymphopoiesis (Chen et al., 2004) , miR-375 regulates insulin secretion by targeting myotrophin mRNA (Poy et al., 2004) , and the miR-let7 family may play a role in oncogenesis via RAS oncogene mRNAs (Johnson et al., 2005) . miR-15a and miR-16-1 are deleted or downregulated in the majority of chronic lymphocytic leukemia (Calin et al., 2005) . Functional studies indicated that miR-221 and -222 inhibit normal erythropoiesis and erythroleukemic cell growth at least in part via Kit receptor downmodulation (Felli et al., 2005) , and their ectopic overexpression directly results in p27 kip1 downregulation in aggressive prostate carcinoma (Galardi et al., 2007) . Lung tumors are among the most deadly types of cancer. Advances in standard treatments for this tumor, such as surgery, radiotherapy and chemotherapy, have not significantly increased patient survival. One of the most important issues that affects survival rate is resistance to therapeutic drugs. Only 20-30% of treated non-small cell lung cancer (NSCLC) patients have clinical evidence of a response. Therefore, the development of new therapeutic strategies is necessary for the treatment of this type of cancer. The Apo2L/tumor necrosis factor (TNF)-a-related apoptosis-inducing ligand (TRAIL) is a relatively new member of the TNF family known to induce apoptosis in a variety of cancers (Schaefer et al., 2007) . TRAIL can bind to five receptors, of which four are located at the cell surface: TRAIL-R1 (DR4), TRAIL-R2 (DR5), TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2). Only two of these receptors, R1 and R2, contain a functional cytoplasmic death domain motif and are capable of delivering the apoptotic signal of TRAIL by association of the death domain with the Fas-associated death domain protein (FADD), containing the death effector domain, which is involved in the activation of caspase 8 (Falschlehner et al., 2007) . The other two receptors, DcR1 and DcR2, are 'decoy receptors' and lack the ability to initiate the apoptotic cascade. Treatment with TRAIL induces programmed cell death in a wide range of transformed cells, both in vitro and in vivo, without producing significant effects in normal cells (Falschlehner et al., 2007; Schaefer et al., 2007) . However, a significant proportion of human cancer cells are resistant to TRAIL-induced apoptosis, and the mechanism of sensitization seems to differ among cell types. Different studies relate resistance to TRAIL-induced cell death to downstream factors. It has been shown that downregulation of PED or cellular FLICE-like inhibitory protein (c-Flip) can sensitize cells to TRAIL-induced apoptosis (Fulda et al., 2000; Garofalo et al., 2007) . However, the mechanism of TRAIL resistance is still largely unknown.
In this study, to identify novel mechanisms implicated in TRAIL resistance, we performed a genome-wide expression profiling of miRs in four different cell lines. We found that miR-221 and -222 are markedly upregulated in TRAIL-resistant, and downregulated in TRAIL-sensitive, NSCLC cells. Our experiments indicate that miR-221 and -222 modulate TRAIL sensitivity in lung cancer cells mainly by modulating p27 kip1 expression and TRAIL-induced caspase machinery.
Results
The cytotoxic effects of TRAIL in human non-small cell lung cancer We analysed TRAIL sensitivity of different human NSCLC cell lines: A459, A549, CALU-1 and H460. Cells were exposed to TRAIL for 24 and 48 h ( Figure 1a ) after which cell death was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay or by fluorescence-activated cell sorting (FACS) with annexin V and propidium iodide staining (data not shown). As shown in Figure 1a , H460 cells underwent TRAIL-induced cell death whereas CALU-1 cells did not display sensitivity when exposed to soluble TRAIL; A459 and A549 cells showed an intermediate sensitivity. A possible mechanism of the differential sensitivity of the tested cells to TRAILinduced apoptosis could be due to the variability of the cell surface levels of the death receptors resulting in increased apoptotic signaling in the sensitive cells. However, functional TRAIL receptor isoforms (TRAIL-R1 and -R2) analysed by western blot (Figure 1b ) or FACS analysis (data not shown) revealed comparable levels of expression in TRAIL-sensitive compared to TRAIL-resistant cells. Furthermore, although H460 cells express low levels of DcR1, the expression of DcR2 receptor is greater compared to CALU-1. Therefore, the expression of the decoy receptors within the two cell lines is balanced. miRs expression screening in TRAIL-resistant versus -sensitive NSCLC cell lines To investigate the involvement of miRs in TRAIL resistance, we analysed the miRs expression profile in TRAIL-resistant (CALU-1) and semi-resistant NSCLC cell lines (A459 and A549) versus TRAIL-sensitive cell line (H460). The analysis was performed with a microarray chip containing 1150 miR probes, including 326 human and 249 mouse miRs, spotted in duplicates (Liu et al., 2004) . Pair-wise significance analysis (PAM) of the microarray indicated that five miR genes were significantly overexpressed in resistant NSCLC cells with a >1.5-fold change (Figure 2 ). These miRs were miR-222, -100, -221, -125b and -15b (Table 1) . Three of these miRs, miR-222, -221 and -100, showed dramatic overexpression with 5-to 8-fold higher levels in resistant ) and DcR1 and DcR2 antibodies (0.5 mg ml NSCLC cells compared to the sensitive NSCLC cells. Downregulation occurred for only two miRs, miR-9 and -96 (Table 1) . To validate the microarray analysis, we performed quantitative real-time-polymerase chain reaction (qRT-PCR) of the most overexpressed miRs (miR-222, -100, -221, -125b) and of the downregulated miR-9 in NSCLC cells. The analysis confirmed the results obtained by the microarray (Figure 3a) . The expression of miR-222 in NSCLC cells was also confirmed with Northern blot (Figure 3b ).
Role of miR-221 and -222 in TRAIL resistance in NSCLC To test the role of these overexpressed miRs in TRAIL sensitivity in lung cancer, we transfected H460 TRAIL-sensitive cells with pre-miR-221 and -222. Increased expression of these miRs upon transfection was confirmed by real-time PCR (data not shown). Overexpression of miR-221 and -222 in H460 cells made these cells more resistant to TRAIL-induced cell death by about 40%, as assessed by MTT assay (Figure 4a ). Xp11.3 5.9 has-miR-125b 11q23-24 5.4 has-miR-15b 3q26.1 3.6 hasmiR96 7q32.2 0.5 has-miR-9 1q23.1 0.072
All differentially expressed miRs have Qo0.01 (false-positive rate). t-Test, Po0.05. These miRs were identified by PAM as predictor of NSCLC with the lowest misclassification error. All the miRs, except miR-9 and -96, are upregulated in the TRAIL-resistant cells compared to the TRAIL-sensitive one.
The same results were obtained by annexin V-fluorescein isothiocyanate (FITC) staining ( Figure 4b ). Interestingly, pre-miR-100 also increased TRAIL sensitivity, while pre-miR-125b and control miR overexpression did not produce any effect (data not shown). We also tested the effects of miRs 221 and 222 on the activation of caspase 8, 3 and poly-(ADP-ribose)polymerase (PARP). Interestingly, while in H460 cells, TRAIL induced the activation of caspase cascade, as assessed by the appearance of the cleaved fragment, the co-incubation of TRAIL with pre-miRs 221 or 222 induced a reduction of TRAIL-mediated cell death machinery activation ( Figure 4c ). We also tested the effect of miR-221 and -222 on the expression of some of TRAIL signaling molecules. Interestingly, Mcl-1 and FADD were upregulated, suggesting an indirect effect of those miRs. TRAIL receptors expression was not affected by miR-221 and -222 upmodulation ( Figure 4e ). Anti-miR inhibitors are sequence-specific nucleotides that specifically target and knock down individual miR molecules. We transfected CALU-1 TRAIL-resistant cells with anti-miR inhibitors -221 and -222 and then assessed TRAIL sensitivity. The levels of miR-221 and -222, assessed by real time (RT)-PCR, were reduced (data not shown). Interestingly, the inhibition of miR-221 and -222 expression with the specific anti-miR inhibitor was able to change the insensitive TRAIL phenotype to a sensitive one (Figure 5a ). A scrambled nonspecific anti-miR did not produce any effect. TRAIL receptors expression was not affected by miR-221 and -222 downmodulation ( Figure 5b ).
p27
kip1 and Kit expression in NSCLC We analysed the predicted targets of the three most significantly overexpressed miRNAs (miR-222, -100 and -221) in TRAIL-resistant cells. In this study, we focused on miR-221 and -222, which are located close to each other on the short arm of the X chromosome. The concordant expression pattern in NSCLC suggested shared regulatory mechanisms for the expression of these two clustered miRs. They are upregulated in Total 5 mg of RNA in 10 ml PCR reaction was used. TaqMan DC T values were converted into absolute copy numbers using a standard curve from synthetic lin-4 miRNA. Data are expressed as the relative expression of the different miRs, compared to 18S rRNA. miRs 222, 100, 221, 125b were markedly upmodulated in resistant but not in sensitive cell cultures, while miR-9 was markedly downmodulated. (b) Northern blot analysis of miR-222 expression. RNA (10 mg) was loaded onto a precast 15% denaturing polyacrylamide gel (Bio-Rad). RNA was then electrophoretically transferred to BrightStar blotting membranes and membrane incubated with labeled miR-222 probe. miR-222 was strongly upregulated in TRAIL-resistant CALU-1 cells.
TRAIL-resistant NSCLC cells and may promote TRAIL resistance by blocking expression of key functional proteins. Different studies have demonstrated that both the proto-oncogene Kit and the tumor suppressor p27 kip1 are miR-221 and -222 targets (Felli et al., 2005; He et al., 2005; Poliseno et al., 2006; le Sage et al., 2007) . We thus investigated Kit and p27 kip1 expression in NSCLC cells. Western blotting of NSCLC cells with a monoclonal anti-Kit antibody revealed two bands of B140 and 120 kDa, corresponding to the mature fully and the partially glycosylated Kit isoforms (Tamborini et al., 2004; Figure 6a ). Interestingly, Kit protein was markedly upregulated in sensitive, and downregulated in resistant, NSCLC cells. FACS analysis, used for quantitative determination of cell surface Kit-receptor expression (Figure 6b ), confirmed the western blot results. Next, we analysed p27 kip1 expression in NSCLC cells. Interestingly, as for Kit, western blot analysis showed that p27 kip1 is clearly detectable in H460 cells, is reduced in A459 and A549 cells, and completely absent in CALU-1 cells (Figure 6a ). Kit and p27 kip1 were both targets of miR-221 and -222 in human NSCLC cells since their expression was modulated in CALU-1 cells upon anti-miR-222 transfection or in H460 cells treated with pre-miR-221 and -222 (Figure 6c) . Furthermore, p27 kip1 was downregulated in Role of the miR-221 and -222 targets, p27 kip1 and Kit, on TRAIL-mediated apoptosis in NSCLC To investigate whether p27 kip1 or Kit were involved in TRAIL resistance, we silenced these genes with specific siRNAs and then evaluated TRAIL sensitivity. Specific anti-Kit or anti-p27 kip1 siRNAs induced a reduction of ) or mouse mAb 002 (isotype control) followed by 10 ml of secondary antibody, Fluorescein-conjugated goat F(ab')2, as described in 'Experimental procedures' section. Surface and total Kit expression was higher in the H460 cells. (c) CALU-1 cells were transfected with 100 nmol of anti-microRNAs (miR)-221 and -222 for 48 h. Total extract (50 mg) was loaded onto 7.5-12% SDS-PAGE. The membrane was blotted with anti-Kit (0.2 mg ml À1 ) or anti-p27 kip1 (1 mg ml
À1
) antibody. Loading control was obtained with anti-b-actin antibody (1:5000). Anti-miR-221 and -222 were able to increase Kit and p27 kip1 expression. (d) p27 kip1 expression upon miR-222 and -221. Cells were transfected with either scrambled or miR-221 and -222 and p27 kip1 expression was assessed by western blot. miR-222 and -221 were able to downregulate p27 kip1 expression.
endogenous expression of Kit or p27 kip1 proteins by about 70% (Figures 7a and d) . To evaluate the role of p27 kip1 and Kit in these cells, we measured survival after treatment with TRAIL. Surprisingly, anti-p27 kip1 siRNA transfection increased H460 cell resistance to TRAIL as assessed by annexin V staining (Figure 7b ) or PARP and caspase 8 activation ( Figure 7c) ; on the contrary anti-Kit siRNA transfection (Figure 7e ).
Discussion
Apoptosis-based anticancer therapies are designed to achieve tumor eradication through the use of deathinducing molecules capable of activating the apoptotic program selectively in neoplastic cells. Owing to its specific toxicity for malignant cells, recombinant forms of TRAIL are among the most promising apoptosisbased antitumor agents (Walczak et al., 1999; Walczak and Krammer, 2000) . Therapy based on the use of agonistic TRAIL receptor antibodies is now in phase 2 clinical trial in different kinds of cancer, included NSCLC (Koschny et al., 2007) . However, in a number of patients, tumor cells evade death signals generated by drugs through the activation of effective antiapoptotic mechanisms (Brown and Attardi, 2005; Ghobrial et al., 2005) . The aim of the present study was to identify specific signatures as potential therapeutic targets for the TRAIL-resistant phenotype in non-small cell lung cancer (NSCLC).
For this purpose, we analysed miRs expression profile in TRAIL-resistant (CALU-1) and semi-resistant NSCLC cell lines (A459 and A549) versus a TRAILsensitive cell line (H460). We identified five miRs MicroRNA and TRAIL resistance in lung cancer M Garofalo et al upregulated in the resistant cell lines (miR-222, -100, -221, -125b and -15b) and between these we further analysed four of them with the highest fold change (miR-222, -100, -221 and -125b) . This pattern was specific for NSCLC cells since we did not find the same pattern in breast cancer cells analysed with the same array (data not shown).
Forced overexpression of the miR-222, -100 and -221, but not of miR-125b, in the sensitive H460 cells increased resistance to TRAIL in these cells, thus indicating that repression of their target proteins is implicated in causing TRAIL resistance. Kept together, our results show that the sensitivity of a cancer cell to a defined external signal is dictated by the expression of a small number of miRs.
Further, to support the involvement of miR-mediated regulation of protein levels in TRAIL resistance, we investigated the potential protein targets of miRs identified in our screening. We focused on the two highly related miRs, miR-221 and -222, that recognize several predicted target genes involved in intracellular signaling (and cell death), and thus good candidate regulators of cell response to TRAIL.
Recent reports revealed that the receptor tyrosine kinase Kit and the cyclin-dependent kinase (cdk) inhibitor, p27 kip1 , are both miR-221 and -222 functional targets (Felli et al., 2005; He et al., 2005; Poliseno et al., 2006; le Sage et al., 2007 ). Here we demonstrate that silencing of p27 kip1 , but not of Kit, increases TRAIL resistance. This result well supports the implication of miR-221 and -222 in determining the resistant/sensitive phenotype in NSCLC cells, and indicates p27 kip1 among target proteins that contribute to maintain cell sensitivity to TRAIL-induced cell death. Taken together these results indicate that even though miR-221 and -222 regulate the levels of both p27 kip1 and Kit proteins, their effects on TRAIL sensitivity are mainly mediated by p27 kip1 . However, it seems plausible that silencing of other additional targets of miR-221 and -222 contributes to TRAIL resistance in NSCLC cells. miR-221-and -222-mediated downregulation of p27 kip1 has been implicated in maintaining a more aggressive cancer phenotype, thus indicating p27 kip1 as bona fide tumor suppressor (Galardi et al., 2007) . p27 kip1 is a member of cdk inhibitory proteins with putative tumor suppressor functions (Sherr and Roberts, 1999) . More recently, p27 kip1 has been described to play different roles depending on the cell type context and on its cytosolic or nuclear cellular localization (Blain et al., 2003; Coqueret, 2003) . The functions of p27 kip1 in the apoptotic process remain unclear. Adenovirus-mediated transient overexpression of p27 kip1 was demonstrated to induce apoptosis in transfected cell (Craig et al., 1997; Katayose et al., 1997) . Other reports describe p27 as antiapoptotic gene (St Croix et al., 1996; Eymin et al., 1999) . Therefore, this suggests that the survival effects of p27 kip1 are cell-type specific and may be mediated by p27 effects on antiapoptotic protein expression (Eymin et al., 1999; Woltman et al., 2003) . Whether similar molecular mechanisms underlie the increase in TRAIL resistance upon silencing of p27 kip1 remains to be further investigated.
The role of miRs in the regulation of TRAIL signaling has been described, although not in lung cancer. Mott et al. (2007) described that miR-29b is able to regulate Mcl1-1 protein and thus TRAIL-mediated cytotoxicity in cholangiocarcinoma cell lines. Corsten et al. (2007) demonstrated that the combined effect of miR-21 antagonism and soluble TRAIL delivery in glioma cells leads to increase in caspase activity and cell death in glioma cells. More recently, Ovcharenko et al. (2007) described a genome-scale miRs and RNAi screen in breast cancer cells. They found a number of different miRs that target TRAIL signaling molecules. Interestingly, they have also found an interrelationship between cell cycle regulation and apoptosis signal transduction pathways.
In conclusion, our results demonstrate that the intracellular levels of few miRs may modulate sensitivity of NSCLC cells to a death receptor ligand with important implications in the design of new therapeutic agents.
Experimental procedures
Materials Media, sera and antibiotics for cell culture were from Life Technologies, Inc. (Grand Island, NY, USA). Protein electrophoresis reagents were from Bio-Rad Laboratories (Richmond, VA, USA) and western blotting and ECL reagents from GE Healthcare (Piscataway, NJ, USA). All other chemicals were from Sigma (St Louis, MO, USA).
Cell culture
Human CALU-1 and A549 NSCLC cell lines were grown in Dulbecco's modified Eagle's medium containing 10% heat-inactivated fetal bovine serum (FBS) and with 2 mM L-glutamine and 100 U ml À1 penicillinstreptomycin. H460 and A459 cell lines were grown in RPMI containing 10% heat-inactivated FBS and with 2 mM L-glutamine and 100 U ml À1 penicillin-streptomycin.
Western blotting
Total proteins from CALU-1, A459, A549 and H460 cells were extracted with radioimmunoprecipitation assay (RIPA) buffer (0.15 mM NaCl, 0.05 mM TrisHCl, pH 7.5, 1% Triton, 0.1% SDS, 0.1% sodium deoxycholate and 1% Nonidet P40). Sample extract (50 mg) was resolved on 7.5-12% SDS-polyacrylamide gels (PAGE) using a mini-gel apparatus (Bio-Rad Laboratories) and transferred to Hybond-C extra nitrocellulose. Membranes were blocked for 1 h with 5% nonfat dry milk in Tris-buffered saline containing 0.05% Tween 20, incubated for 2 h with primary antibody, washed and incubated with secondary antibody, and visualized by chemiluminescence. The following primary antibodies were used: Kit (R&D System, Minneapolis, MN, USA), and a secondary anti-goat immunoglobulin G (IgG) antibody peroxidase conjugate (Chemicon, Pittsburg, PA, USA); anti-TRAIL-R1, -R2, -R3 and -R4 (Santa Cruz Inc., Santa Cruz, CA, USA), anti-p27 kip1 (Santa Cruz Inc), anti-caspase 8 (Cell Signaling, Danvers, MA, USA), anti-caspase 3 and anti-PARP (Santa Cruz Inc), anti-b-actin antibody (Sigma), anti-Mcl-1, anti-Bcl2,FADD (Santa Cruz), anti-FLIP (Alexis Biochemicals, Lausen, Switzerland). Expression levels were analysed with Scion Image.
FACS analysis
For flow cytometry analysis of cell surface Kit, cells were stained with primary antihuman h-SCFR affinitypurified goat IgG or mouse mAb 002 (isotype control, both from R&D Systems), followed by secondary antibody, Fluorescein-conjugated goat F(ab')2 (R&D Systems).
Cell death and cell proliferation quantification Cells were plated in 96-well plates in triplicate and incubated at 37 1C in a 5% CO 2 incubator. Super-Killer TRAIL (Alexis Biochemicals) was used for 24-48 h at 400 ng ml À1 . Cell viability was evaluated with the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA), according to the manufacturer's protocol. Metabolically active cells were detected by adding 20 ml of MTT to each well. After 2 h of incubation, the plates were analysed in a Multilabel Counter (Bio-Rad Laboratories). Apoptosis was assessed using annexin V-FITC apoptosis detection kits followed by flow cytometric analysis. Cells were seeded at 1.8 Â 10 6 cells per 100 mm dish, grown overnight in 10% FBS/RPMI, washed with phosphate-buffered saline (PBS) and then treated for 24 h with 200 ng TRAIL. Following incubation, cells were washed with cold PBS and removed from the plates by trypsinization. The resuspended cells were washed with cold PBS and stained with FITC-conjugated annexin V antibody according to the manufacturer's instructions (Roche Applied Science, Indianapolis, IN, USA). Cells (50 000 per sample) were then subjected to flow cytometric analysis. Flow cytometry analyses were done as described (Garofalo et al., 2007) . The fraction of H460 cells treated with TRAIL was taken as the apoptotic cell population. The percentage of apoptosis indicated was corrected for background levels found in the corresponding untreated controls.
RNA extraction and Northern blotting
Total RNA was extracted with TRIzol solution (Invitrogen, Carlsbad, CA, USA) and the integrity of RNA was assessed with an Agilent BioAnalizer 2100 (Agilent, Palo Alto, CA, USA). Northern blotting was performed as described (Calin et al., 2002) . Total RNA (10 mg) from cell lines was loaded onto a precast 15% denaturing polyacrylamide gel (Bio-Rad). The RNA was then electrophoretically transferred to BrightStar blotting membranes (Ambion, Austin, TX, USA). The oligonucleotides used as probes were the complementary sequences of the mature miRNA (miRNA registry): miR-221, 5 0 -GAAACCCAGCAGACAATGTAGCT-3 0 ; miR-222, 5
0 -GAGACCCAGTAGCCAGATGTAGCT-3 0 .
miR probes were end-labeled with [g-32 P]-ATP by T4 polynucleotide kinase (USB, Cleveland, OH, USA). Prehybridization and hybridization were carried out in Ultrahyb Oligo solution (Ambion) containing 10 6 c.p.m. per ml probes overnight at 37 1C. The most stringent wash was with 2 Â SSC and 1% SDS at 37 1C. For reuse, blots were stripped by boiling and reprobed. As a loading control U6 rRNA was used. The image of Northern hybridization signals was produced by using Stormscanner and ImageQuant TL softwares (Molecular Dynamics, Sunnyvale, CA, USA).
miRNA microarray experiments Total RNA (5 mg) from each sample was reverse transcribed using biotin end-labeled random octamer oligonucleotide primer. Hybridization of biotin-labeled complementary DNA was performed on a new Ohio State University custom miRNA microarray chip (OSU_CCC version 3.0), which contains 1150 miRNA probes, including 326 human and 249 mouse miRNA genes, spotted in duplicates. The hybridized chips were washed and processed to detect biotin-containing transcripts by streptavidin-Alexa647 conjugate and scanned on an Axon 4000B microarray scanner (Axon Instruments, Sunnyvale, CA, USA).
Raw data were normalized and analysed in Genespring 7.2 software (zcomSilicon Genetics, Redwood City, CA, USA). Expression data were median centered by using both the Genespring normalization option and the global median normalization of the Bioconductor package (www.bioconductor.org) with similar results. Statistical comparisons were done by using the Genespring ANOVA tool, Predictive Analysis of Microarray and the Significance Analysis of Microarray softwares (http://www-stat.stanford.edu/Btibs/SAM/index.html).
Real-time PCR
Real-time PCR was performed using a standard TaqMan PCR Kit protocol on a 7900HT Sequence Detection System (P/N 4329002, Applied Biosystems, Austin, TX, USA). The 10 ml PCR reaction included 0.67 ml RT product, 1 ml TaqMan Universal PCR Master Mix (P/N 4324018, Applied Biosystems), 0.2 mM TaqMan probe, 1.5 mM forward primer and 0.7 mM reverse primer. The reactions were incubated in a 96-well plate at 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min. All reactions were run in triplicate. The threshold cycle (C T ) is defined as the fractional cycle number at which the fluorescence passes the fixed threshold. The comparative C T method for relative quantization of gene expression (User Bulletin no. 2, Applied Biosystems) was used to determine miRNA expression levels. The y axis represents the 2 ðÀDC T Þ , or the relative expression of the different miRs. miRs expression was calculated relative to 18S rRNA and multiplied by 10 4 . Experiments were carried out in triplicate for each data point, and data analysis was performed by using software (Bio-Rad).
Transfection of Pre-miRs and anti-miR miRNA inhibitors in NSCLC cells TRAIL-sensitive cell lines (H460) were cultured to 80% confluence in p60 plates with a serum-free medium without antibiotics and then transfected with 100 nmol of pre-miR-221 and -222 oligonucleotides or negative control for 48 h (Ambion). CALU-1 cells were cultured to 80% confluence in p60 plates with a serum-free medium without antibiotics. Total 100 nmol of 221 and 222 anti-miR inhibitors (Ambion) were transiently transfected in cells using Lipofectamine 2000 according to manufacturer's instructions. Cells were incubated in the presence of the specific anti-miR inhibitors and negative control (a random sequence anti-miR molecule) for 48 h. Subsequently, TRAIL-induced cell death was analysed as previously described.
Anti-p27
kip1 siRNA transfection in NSCLC H460 cells were cultured to 80% confluence and transiently transfected using Lipofectamine 2000 with anti-p27 kip1 siRNA (Santa Cruz), a pool of four targetspecific 20-25 nt siRNAs designed to knock down gene expression. p27 kip1 siRNA (20 nmol) was transfected with 6 ml transfection reagent, as described in the manufacturer's protocol.
Statistical analysis
Continuous variables are expressed as mean values± standard deviation (s.d.). The Student's t-test was used to determine the role of miRs, anti-miRs, Kit or p27 expression on NSCLC cells apoptosis. Po0.05 was considered significant.
